The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of parkinson's disease

Folia Histochemica et Cytobiologica

Volumn 48, Issue 3, 2010, Pages 434-441

  Tanriover, Gamze ^a   Seval Celik, Yasemin ^a   Ozsoy, Ozlem ^a   Akkoyunlu, Gokhan ^a   Savcioglu, Feyza ^a   Hacioglu, Gulay ^a   Demir, Necdet ^a   Agar, Aysel ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

DHA; GDNF; NTN; Parkinson's disease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; D 2354; DOCOSAHEXAENOIC ACID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURTURIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

RATTUS;

EID: 78649576567     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-010-0047-6     Document Type: Article

References (27)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415-455.
2. Carlsson A. Thirty years of dopamine research. Adv Neurol. 1993;60:1-10.
3. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24:574-576.
4. Florent S, Malaplate-Armand C, Youssef I, et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem. 2006;96:385-395.
5. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. PNAS. 2005;102:10858-10863.
6. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem. 2004;90:979-988.
7. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci. 2003;116:3855-3862.
8. Gash DM, Zhang Z, Gerhardt G. Neuroprotective and neurorestorative properties of GDNF. Ann Neurol. 1998;44: S121-125.
9. Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci. 1998;18:4929-4937.
10. Hacioglu G, Agar A, Yargicoglu P. The role of docosahexaenoic acid on visual evoked potentials in one kidney-one clip hypertension. Acta Ophthalmol candinavica. 2006;84: 488-494.
11. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods. 2005;148:78-87.
12. Pellegrino LJ PA, Cushman AJ. Stereotaxic Atlas of the Rat Brain. New York: Plenum Press, 1979.
13. Crawley J. What's wrong with my mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. 2000;Wiley-Liss, New York.
14. Papeschi R, Theiss P, Ayhan H. AMT catalepsy and hypokinesia: interaction with morphine and cocaine. Psychopharmacologia. 1976;46:149-157.
15. Tanriover G, Demir N, Pestereli E, Demir R, Kayisli UA. PTEN-mediated Akt activation in human neocortex during prenatal development. Histochem Cell Biol. 2005;123:393-406.
16. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine. Life Sci. 1985;36:2503-2508.
17. Beal MF. Experimental models of Parkinson's disease. Nature Reviews. 2001;2:325-334.
18. Grofova I. Extrinsic connections of the neostriatum. Oxford: The Neostriatum, Pergamon Press, 1979.
19. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res. 1999;828:91-103.
20. Petursdottir AL, Farr SA, Morley JE, Banks WA, Skuladottir GV. Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse. J Gerontol. 2008;63:1153-1160.
21. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J Nutr. 2008;138:2510-2514.
22. Kato H, Kurosaki R, Oki C, Araki T. Arundic acid, an astrocyte- modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res. 2004;1030: 66-73.
23. Akerud P, Alberch J, Eketjall S, Wagner J, Arenas E. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem. 1999;73:70-78.
24. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130-1132.
25. Grondin R, Gash DM. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol. 1998;245:P35-42.
26. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nature Reviews. 2002;3:383-394.
27. Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22:1763-1771.